Comparative Pharmacology
Head-to-head clinical analysis: CARBIDOPA LEVODOPA versus DOPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBIDOPA LEVODOPA versus DOPAR.
CARBIDOPA; LEVODOPA vs DOPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa availability in the CNS and reducing peripheral side effects.
DOPAR (levodopa) is a metabolic precursor of dopamine. It crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase (AADC) in the brain, thereby replenishing striatal dopamine levels and alleviating symptoms of Parkinson's disease.
Initial: carbidopa 25 mg/levodopa 100 mg (1 tablet) orally three times daily; titrate based on response. Maintenance: usually 1 tablet (25/100) three to four times daily, up to 8 tablets/day. Immediate-release, extended-release, and oral disintegrating forms available.
Levodopa 300-600 mg orally 3-4 times daily as Dopar; do not crush or chew extended-release.
None Documented
None Documented
Levodopa: 1-3 hours (short, requires frequent dosing); carbidopa: 1-2 hours. Clinically, the combination extends half-life but does not significantly alter terminal elimination.
Terminal half-life: 1-3 hours (levodopa alone); with carbidopa (Sinemet): 1.5-2 hours due to reduced peripheral metabolism; clinical context: short half-life requires frequent dosing (every 4-6 hours) to maintain therapeutic levels.
Levodopa: primarily renal (70-80% as metabolites, including dopamine and homovanillic acid); carbidopa: renal (30% unchanged, remainder as metabolites). Fecal excretion is minimal (<5%).
Renal: 70-80% as metabolites (including homovanillic acid, dihydroxyphenylacetic acid, and 3-O-methyldopa); biliary/fecal: ~20% as conjugates and metabolites; unchanged levodopa <1%.
Category A/B
Category C
Dopamine Precursor
Dopamine Precursor